维普期刊资源整合服务平台（V6.5）

177篇 您的检索式：作者名="Zangari"

选中清除导出查看参考文献查看引证文献引用追踪共9页首页上一页第1页下一页末页 /9 跳转

	题名	作者	年代	出处	被引量
1	Thalidomide in the management of multiple myeloma显示文摘	Barlogie B Zangari M Spencer T		0，，：	2
2	Increased risk of deep - vein thrombosis in patients with multiplmyeloma receiving thalidomide and chemotherapy显示文摘	Zangari M Anaissie E Barlogic B	2001	Blood2001，98，5：	1
3	A VaR Methodology for Portfolios that include Options显示文摘	Zangari P	1996	Risk Metrics Monitor1996，，：	1
4	Thalidomide in the management of multiple myeloma 显示文摘	BARLOGIC B ZANGARI M SPENCER T	2001	Semin Hematol2001，38，：	1
5	Electrodeposition of sacrificial tin- manganese alloy coatings显示文摘	Gong J Zangari G	2003	Materials Science and Engineering2003，344，12：	1
6	VTD combination therapy with bortezomib-thalidomide-dexamethasone ib highly effective in advanced and refractory multiple myeloma显示文摘	Pineda-Roman M Zangari M Van Rhe F	2008	Leukemia2008，22，7：	1
7	Thrombotic events in patients with cancer receiving antiangiogenesis agents 显示文摘	Zangari M Fink L M Elice F	2009	J Clin Oncol2009，27，29：	1
8	The blood coagulation mechanism in multiple myeloma显示文摘	Zangari M Saghafifar F Mehta P	2003	Semin Thromb Hemost2003，29，3：	1
9	Quantitative bone ul trasound at phalanges and calcanues in osteoporotic postmenopausal women: influence of age and measurement site显示文摘	Camozzi V De Terlizzi F Zangari M	2007	Ultrasound Med Biol2007，33，7：	1
10	Velcade (V)- Thalidomide(T)-Dexamethasone(D)for Advanced and Refractory Multiple Myeloma (MM) : Long-Term Follow-Up of Phase Ⅰ-Ⅱ Trail UARK 2001-37: Superior Outcome in Patients with Normal Cytogenetics and No Prior T 显示文摘	ZANGARI M BARLIGIE B BURNS M	2005	Blood (ASH Annual Meeting Abstracts)2005，106，：	1
11	Electrodeposition and characterization of manganese coatings显示文摘	GONG J ZANGARI G	2002	Journal of the Electrochemical Society2002，149，4：	1
12	Increaseed risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy 显示文摘	Zangari M Anaissie E Barlogie B	2001	Blood2001，98，5：	1
13	VTD combination therapy with bortezomib-thalidomide-dexamethasone ib highly effective in advanced and refractory multiple myeloma显示文摘	Pineda-Roman M Zangari M Van Rhe F	2008	Leukemia2008，22，7：	1
14	Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy显示文摘	Zangari M Anaissie E Barlogie B	2001	Blood2001，98，5：	1
15	Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy 显示文摘	ZANGARI M SIEGEL E BARLOGIE B	2002	Blood2002，100，：	1
16	Tailor- ing morphology in free-standing anodic aluminium ox?ide: control of barrier layer opening down to the sub- 10nm diameter显示文摘	Jie Gong William H But lera Giovanni Zangari	2010	Nanoscale2010，2，：	1
17	VTD combination therapy with bortezomib-thalidomide- dexamethasone is highly effective in advanced and refractory multiple myeloma 显示文摘	PINEDA-ROMAN M ZANGARI M VAN RHEE F	2008	Leukemia2008，22，7：	1
18	Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients显示文摘	Maurizio Zangari Bart Barlogie Federica Cavallo Vanessa Bolejack Louis Fink Guido Tricot	2007	Blood Coagulation & Fibrinolysis2007，，7：	1
19	Hemostatic dysfunction in paraproteinemias and amyloidosis显示文摘	Zangari M Elice F Fink L	2007	Semin Thromb Hemost2007，33，4：	1
20	Beyond the CRAB symptoms:a study of presenting clinical manifestations of multiple myeloma显示文摘	Talamo G Farooq U Zangari M		0，，：	1

返回顶部每页显示：

共9页首页上一页第1页下一页末页 /9 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示